Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Accumulated Expenses: 2010-2024

Historic Other Accumulated Expenses for Ligand Pharmaceuticals (LGND) over the last 6 years, with Dec 2024 value amounting to $1.3 million.

  • Ligand Pharmaceuticals' Other Accumulated Expenses was N/A to $135,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $135,000, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A change from last year.
  • Ligand Pharmaceuticals' Other Accumulated Expenses amounted to $1.3 million in FY2024, which was up 184.90% from $457,000 recorded in FY2022.
  • In the past 5 years, Ligand Pharmaceuticals' Other Accumulated Expenses ranged from a high of $1.3 million in FY2024 and a low of $457,000 during FY2022.
  • For the 2-year period, Ligand Pharmaceuticals' Other Accumulated Expenses averaged around $879,500, with its median value being $879,500 (2022).